Cover Image
市場調查報告書

下一代癌症診斷市場規模與預測:次世代定序,PRC、多工處理,實驗室晶片,蛋白質微陣列,DNA微陣列)

Next Generation Cancer Diagnostics Market Size & Forecasts By Technology (NGS, LOAC & RT-PCR), By Application (CTC, Biomarker), By Cancer Type (Lung, Breast), By Function Companion Diagnostics), And Trend Analysis, 2013 - 2024

出版商 Grand View Research, Inc. 商品編碼 355251
出版日期 內容資訊 英文 138 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
下一代癌症診斷市場規模與預測:次世代定序,PRC、多工處理,實驗室晶片,蛋白質微陣列,DNA微陣列) Next Generation Cancer Diagnostics Market Size & Forecasts By Technology (NGS, LOAC & RT-PCR), By Application (CTC, Biomarker), By Cancer Type (Lung, Breast), By Function Companion Diagnostics), And Trend Analysis, 2013 - 2024
出版日期: 2017年01月04日 內容資訊: 英文 138 Pages
簡介

本報告提供全球下一代癌症診斷市場現狀與今後的成長預測,各技術、用途、功能、癌症的種類、地區的趨勢,以及主要企業的簡介等彙整。

第1章 摘要整理

第2章 下一代癌症診斷:產業概要

  • 市場區隔
  • 市場規模與成長預測
  • 市場動態
    • 市場推動因素
    • 市場阻礙因素
  • 主要的市場機會
  • 波特的五力分析
  • PESTEL分析

第3章 技術概要

  • 下一代癌症診斷市場:各技術收益佔有率
  • 次世代定序(NGS)
  • PCR及多工處理
  • 實驗室晶片
  • 蛋白質微陣列
  • DNA微陣列

第4章 下一代癌症診斷市場預測:癌症的各類型

  • 下一代癌症診斷市場:癌症的各類型收益佔有率
  • 肺癌
  • 乳癌
  • 大腸癌
  • 子宮頸癌
  • 其他

第5章 下一代癌症診斷市場預測:各用途

  • 下一代癌症診斷市場:各用途收益佔有率
  • 生物標記開發
  • CTC分析
  • 蛋白質體學分析
  • 表觀遺傳學分析
  • 遺傳基因分析

第6章 下一代癌症診斷市場預測:各功能

  • 下一代癌症診斷市場:各功能收益佔有率
  • 治療監測
  • 搭配診斷
  • 預後診斷
  • 癌症篩檢
  • 風險分析

第7章 下一代癌症診斷市場預測:各地區

  • 下一代癌症診斷市場:各地區收益佔有率
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第8章 競爭環境、企業簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 978-1-68038-738-4

The global next generation cancer diagnostics market is anticipated to reach USD 11.04 billion by 2024, according to a new report by Grand View Research, Inc. Key drivers for this vertical include rising advancement in genomics and proteomics-based research coupled with increasing prevalence of oncology disorders.

Rise in number of oncological research projects to elucidate tumorigenesis and the underlying mechanisms, consequently raising the demand for serial sampling, diagnosis, and therapeutic manipulation, is a growth rendering driver of this market.

Further Key Findings from the Study Suggest:

  • The qPCR & multiplexing segment captured the largest market share in 2015 owing to the presence of a wide product portfolio serving numerous applications in oncology R&D
  • Next generation sequencing services and solutions for oncology applications are anticipated to be the fastest growing segment
  • Oncology diagnostics in biomarker discovery is expected witness growth as it subsequently facilitates drug designing and identification of novel targets against tumors
  • On the basis of cancer type, this vertical is segmented into lung, breast, colorectal, cervical, and other forms of cancer
  • Research projects to establish the therapeutic index of anticancer cytotoxic drugs are one of the key factors responsible for expected growth
  • North America dominated the market with respect to revenue generation in 2014 due to concerted efforts directed toward the development of next generation sequencing technology and companion diagnostics in personalized medicine
  • Some of the key players contributing significantly to the next generation cancer diagnostics market are Novartis AG; Cepheid; Hoffman La Roche Ltd.; PerkinElmer, Inc.; Sysmex Corporation; Abbott; Thermo Fisher Scientific, Inc.; Koninklijke Philips N.V.; Agilent Technologies; Illumina, Inc.; Genomic Health, Inc.; Qiagen; Janssen Global Services, LLC; Hologic, Inc.; Myriad Genetics, Inc.; Almac Group; Opko Health, Inc.; and GE Healthcare.

Table of Contents

Chapter 1 Executive Summary

Chapter 2 Next Generation Cancer Diagnostics Industry Outlook

  • 2.1 Market segmentation
  • 2.2 Market size and growth prospects, 2013 - 2024
  • 2.3 Next generation cancer diagnostics market dynamics
    • 2.3.1 Market driver analysis
      • 2.3.1.1 Exponentially decreasing cost of genetic sequencing
      • 2.3.1.2 Development of cluster chip technology and potential applications of CTC in cancer management
      • 2.3.1.3 Rising demand for preventive medicine & companion diagnostics
      • 2.3.1.4 Growing cancer incidence
    • 2.3.2 Market restraint analysis
      • 2.3.2.1 Requirement of expensive laboratory set-up for implementation of novel tests
  • 2.4 Key Opportunities Prioritized
  • 2.5 Industry analysis - Porter's
  • 2.6 Next Generation Cancer Diagnostics PESTEL Analysis

Chapter 3 Next Generation Cancer Diagnostics Technology Outlook

  • 3.1 Global next generation cancer diagnostics revenue share, by technology, 2015 & 2024
  • 3.2 NGS-based cancer diagnostics
    • 3.2.1 NGS-based cancer diagnostics market, 2013 - 2024 (USD Million)
  • 3.3 qPCR & Multiplexing
    • 3.3.1 qPCR & multiplexing-based market, 2013 - 2024 (USD Million)
  • 3.4 Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
    • 3.4.1 LOAC & RT-PCR-based market, 2013 - 2024 (USD Million)
  • 3.5 Protein microarrays-based cancer diagnostics
    • 3.5.1 Protein microarraysmarket, 2013 - 2024 (USD Million)
  • 3.6 DNA microarrays-based cancer diagnostics
    • 3.6.1 DNAmicroarrays-based cancer diagnosticsmarket, 2013 - 2024 (USD Million)

Chapter 4 Next Generation Cancer Diagnostics Outlook by Cancer Type

  • 4.1 Global next generation cancer diagnostics revenue share, by cancer type, 2015&2024
  • 4.2 Lung cancer
    • 4.2.1 NGCD for lung cancer market, 2013 - 2024 (USD Million)
  • 4.3 Breast cancer
    • 4.3.1 NGCD for breast cancer market, 2013 - 2024 (USD Million)
  • 4.4 Colorectal cancer
    • 4.4.1 NGCD for colorectal cancer market, 2013 - 2024 (USD Million)
  • 4.5 Cervical cancer
    • 4.5.1 NGCD for cervical cancer market, 2013 - 2024 (USD Million)
  • 4.6 Other types of cancer
    • 4.6.1 NGCD for other forms of cancer market, 2013 - 2024 (USD Million)

Chapter 5 Next Generation Cancer Diagnostics Outlook by Application Outlook

  • 5.1 Global next generation cancer diagnostics revenue share, by application, 2015&2024
  • 5.2 Biomarker development
    • 5.2.1 NGCD for biomarker development market, 2013 - 2024 (USD Million)
  • 5.3 CTC analysis
    • 5.3.1 NGCD for CTC analysis market, 2013 - 2024 (USD Million)
  • 5.4 Proteomic analysis
    • 5.4.1 NGCD for proteomic analysis market, 2013 - 2024 (USD Million)
  • 5.5 Epigenetic analysis
    • 5.5.1 NGCD for epigenetic analysis market, 2013 - 2024 (USD Million)
  • 5.6 Genetic analysis
    • 5.6.1 NGCD for genetic analysismarket, 2013 - 2024 (USD Million)

Chapter 6 Next Generation Cancer Diagnostics Outlook by Function

  • 6.1 Global next generation cancer diagnostics revenue share, by function, 2015&2024
  • 6.2 Therapeutic monitoring
    • 6.2.1 NGCD for therapeutic monitoring market, 2013 - 2024 (USD Million)
  • 6.3 Companion diagnostics
    • 6.3.1 NGCD for companion diagnostics market, 2013 - 2024 (USD Million)
  • 6.4 Prognostic diagnostics
    • 6.4.1 NGCD for prognostics market, 2013 - 2024 (USD Million)
  • 6.5 Cancer screening
    • 6.5.1 NGCD for cancer screening market, 2013 - 2024 (USD Million)
  • 6.6 Risk analysis
    • 6.6.1 NGCD for risk analysis market, 2013 - 2024 (USD Million)

Chapter 7 Next Generation Cancer Diagnostics Regional Outlook

  • 7.1 Global next generation cancer diagnostics revenue share, by region, 2015 & 2024
  • 7.2 North America
    • 7.2.1 North America next generation cancer diagnostics market, 2013 - 2024 (USD Million)
    • 7.2.2 U.S.
      • 7.2.2.1 U.S. next generation cancer diagnostics market, 2013 - 2024 (USD Million)
    • 7.2.3 Canada
      • 7.2.3.1 Canada next generation cancer diagnostics market, 2013 - 2024 (USD Million)
  • 7.3 Europe
    • 7.3.1 Europe next generation cancer diagnostics market, 2013 - 2024 (USD Million)
    • 7.3.2 Germany
      • 7.3.2.1 Germany next generation cancer diagnostics market, 2013 - 2024 (USD Million)
    • 7.3.3 France
      • 7.3.3.1 France next generation cancer diagnostics market, 2013 - 2024 (USD Million)
  • 7.4 Asia Pacific
    • 7.4.1 Asia Pacific next generation cancer diagnostics market, 2013 - 2024 (USD Million)
    • 7.4.2 Japan
      • 7.4.2.1 Japan next generation cancer diagnosticsmarket, 2013 - 2024 (USD Million)
    • 7.4.3 China
      • 7.4.3.1 China next generation cancer diagnostics market, 2013 - 2024 (USD Million)
  • 7.5 Latin America
    • 7.5.1 Latin Americanext generation cancer diagnosticsmarket, 2013 - 2024 (USD Million)
    • 7.5.2 Brazil
      • 7.5.2.1 Brazil next generation cancer diagnostics market, 2013 - 2024 (USD Million)
  • 7.6 MEA
    • 7.6.1 MEA next generation cancer diagnostics market, 2013 - 2024 (USD Million)
    • 7.6.2 South Africa
      • 7.6.2.1 South Africa next generation cancer diagnostics market, 2013 - 2024 (USD Million)

Chapter 8 Competitive Landscape

  • 8.1 Janssen Global Services, LLC
    • 8.1.1 Company Overview
    • 8.1.2 Financial Performance
    • 8.1.3 Product Benchmarking
    • 8.1.4 Strategic Initiatives
  • 8.2 Novartis AG
    • 8.2.1 Company Overview
    • 8.2.2 Financial Performance
    • 8.2.3 Product Benchmarking
    • 8.2.4 Strategic Initiatives
  • 8.3 F. Hoffmann-La Roche Ltd
    • 8.3.1 Company Overview
    • 8.3.2 Financial Performance
    • 8.3.3 Product Benchmarking
    • 8.3.4 Strategic Initiatives
  • 8.4 Koninklijke Philips N.V.
    • 8.4.1 Company Overview
    • 8.4.2 Financial Performance
    • 8.4.3 Product Benchmarking
    • 8.4.4 Strategic Initiatives
  • 8.5 Abbott
    • 8.5.1 Company Overview
    • 8.5.2 Financial Performance
    • 8.5.3 Product Benchmarking
  • 8.6 GE Healthcare
    • 8.6.1 Company Overview
    • 8.6.2 Financial Performance
    • 8.6.3 Product Benchmarking
    • 8.6.4 Strategic Initiatives
  • 8.7 Thermo Fisher Scientific, Inc.
    • 8.7.1 Company Overview
    • 8.7.2 Financial Performance
    • 8.7.3 Product Benchmarking
    • 8.7.4 Strategic Initiatives
  • 8.8 Agilent Technologies (Dako)
    • 8.8.1 Company Overview
    • 8.8.2 Financial Performance
    • 8.8.3 Product Benchmarking
    • 8.8.4 Strategic Initiatives
  • 8.9 Illumina, Inc.
    • 8.9.1 Company Overview
    • 8.9.2 Financial Performance
    • 8.9.3 Product Benchmarking
    • 8.9.4 Strategic Initiatives
  • 8.10 Qiagen
    • 8.10.1 Company Overview
    • 8.10.2 Financial Performance
    • 8.10.3 Product Benchmarking
    • 8.10.4 Strategic Initiatives
  • 8.11 Cepheid
    • 8.11.1 Company Overview
    • 8.11.2 Financial Performance
    • 8.11.3 Product Benchmarking
    • 8.11.4 Strategic Initiatives
  • 8.12 Opko Health, Inc.
    • 8.12.1 Company Overview
    • 8.12.2 Financial Performance
    • 8.12.3 Service Benchmarking
    • 8.12.4 Strategic Initiatives
  • 8.13 Hologic, Inc (Gen-Probe)
    • 8.13.1 Company Overview
    • 8.13.2 Financial Performance
    • 8.13.3 Product Benchmarking
    • 8.13.4 Strategic Initiatives
  • 8.14 Perkin Elmer, Inc.
    • 8.14.1 Company Overview
    • 8.14.2 Financial Performance
    • 8.14.3 Product Benchmarking
    • 8.14.4 Strategic Initiatives
  • 8.15 Sysmex Corporation
    • 8.15.1 Company Overview
    • 8.15.2 Financial Performance
    • 8.15.3 Product Benchmarking
    • 8.15.4 Strategic Initiatives
  • 8.16 Myriad Genetics, Inc.
    • 8.16.1 Company Overview
    • 8.16.2 Financial Performance
    • 8.16.3 Product Benchmarking
    • 8.16.4 Strategic Initiatives
  • 8.17 Almac Group
    • 8.17.1 Company Overview
    • 8.17.2 Financial Performance
    • 8.17.3 Product Benchmarking
    • 8.17.4 Strategic Initiatives
  • 8.18 Exosome Diagnostics, Inc.
    • 8.18.1 Company Overview
    • 8.18.2 Financial Performance
    • 8.18.3 Product Benchmarking
    • 8.18.4 Strategic Initiatives
  • 8.19 Genomic Health, Inc.
    • 8.19.1 Company Overview
    • 8.19.2 Financial Performance
    • 8.19.3 Product Benchmarking
    • 8.19.4 Strategic Initiatives

List of Tables

  • TABLE 1 Next Generation Cancer Diagnostics - Industry Snapshot &Key Buying Criteria, 2013 - 2024
  • TABLE 2 Global next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 3 Global next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 4 Global next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
  • TABLE 5 Global next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
  • TABLE 6 Global next generation cancer diagnostics market, by region 2013 - 2024 (USD Million)
  • TABLE 7 Next generation cancer diagnostics key market driver analysis
  • TABLE 8 Global cancer incidence, 2012
  • TABLE 9 North America cancer incidence in 2012
  • TABLE 10 Europe cancer incidence, 2012
  • TABLE 11 Asia cancer incidence, 2012
  • TABLE 12 Africa cancer incidence, 2012
  • TABLE 13 Australia and New Zealand cancer incidence in 2012
  • TABLE 14 Next generation cancer diagnostics key market restraint analysis
  • TABLE 15 North America next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 16 North America next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 17 North America next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
  • TABLE 18 North America next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
  • TABLE 19 U.S. next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 20 U.S. next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 21 U.S. next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
  • TABLE 22 U.S. next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
  • TABLE 23 Canada next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 24 Canada next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 25 Canada next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
  • TABLE 26 Canada next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
  • TABLE 27 Europe next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 28 Europe next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 29 Europe next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
  • TABLE 30 Europe next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
  • TABLE 31 Germany next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 32 Germany next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 33 Germany next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
  • TABLE 34 Germany next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
  • TABLE 35 France next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 36 France next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 37 France next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
  • TABLE 38 France next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
  • TABLE 39 Asia Pacific next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 40 Asia Pacific next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 41 Asia Pacific next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
  • TABLE 42 Asia Pacific next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
  • TABLE 43 Japan next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 44 Japan next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 45 Japan next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
  • TABLE 46 Japan next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
  • TABLE 47 China next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 48 China next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 49 China next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
  • TABLE 50 China next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
  • TABLE 51 Latin America next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 52 Latin America next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 53 Latin America next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
  • TABLE 54 Latin America next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
  • TABLE 55 Brazil next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 56 Brazil next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 57 Brazil next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
  • TABLE 58 Brazil next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
  • TABLE 59 MEA next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 60 MEA next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 61 MEA next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
  • TABLE 62 MEA next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
  • TABLE 63 South Africa next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 64 South Africa next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
  • TABLE 65 South Africa next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
  • TABLE 66 South Africa next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)

List of Figures

  • FIG. 1 Next generation cancer diagnostics market segmentation
  • FIG. 2 Global next generation cancer diagnostics market, 2013 - 2024 (USD Million)
  • FIG. 3 Next generation cancer diagnostics market dynamics
  • FIG. 4 Cost per raw mega base (Mb) of DNA sequence
  • FIG. 5 Cost per genome sequencing
  • FIG. 6 Key opportunities prioritized, 2015 & 2024
  • FIG. 7 Next generation cancer diagnostics market Porter's analysis
  • FIG. 8 Next generation cancer diagnostics market PESTEL analysis
  • FIG. 9 Global next generation cancer diagnostics revenue share, by technology, 2015 & 2024
  • FIG. 10 NGS-based cancer diagnostics market , 2013 - 2024 (USD Million)
  • FIG. 11 qPCR & Multiplexing based market, 2013 - 2024 (USD Million)
  • FIG. 12 LOAC & RT-PCR-based market , 2013 - 2024 (USD Million)
  • FIG. 13 Protein microarrays market, 2013 - 2024 (USD Million)
  • FIG. 14 DNA microarrays-based cancer diagnostics market, 2013 - 2024 (USD Million)
  • FIG. 15 Global next generation cancer diagnostics revenue share, by application, 2015 & 2024
  • FIG. 16 NGCD for lung cancer market , 2013 - 2024 (USD Million)
  • FIG. 17 NGCD for breast cancer market , 2013 - 2024 (USD Million)
  • FIG. 18 NGCD for colorectal cancer market , 2013 - 2024 (USD Million)
  • FIG. 19 NGCD for cervical market, 2013 - 2024 (USD Million)
  • FIG. 20 NGCD for other forms of cancer market, 2013 - 2024 (USD Million)
  • FIG. 21 Global next generation cancer diagnostics revenue share, by application, 2015 & 2024
  • FIG. 22 NGCD for biomarker development market , 2013 - 2024 (USD Million)
  • FIG. 23 NGCD for CTC analysis market , 2013 - 2024 (USD Million)
  • FIG. 24 NGCD for proteomic analysis market , 2013 - 2024 (USD Million)
  • FIG. 25 NGCD for epigenetic analysis market, 2013 - 2024 (USD Million)
  • FIG. 26 NGCD for genetic analysis market, 2013 - 2024 (USD Million)
  • FIG. 27 Global next generation cancer diagnostics revenue share, by function, 2015 & 2024
  • FIG. 28 NGCD for therapeutic monitoring market , 2013 - 2024 (USD Million)
  • FIG. 29 NGCD for companion diagnostics market , 2013 - 2024 (USD Million)
  • FIG. 30 NGCD for prognostics market , 2013 - 2024 (USD Million)
  • FIG. 31 NGCD for cancer screening market, 2013 - 2024 (USD Million)
  • FIG. 32 NGCD for risk analysis market, 2013 - 2024 (USD Million)
  • FIG. 33 Global next generation cancer diagnostics revenue share, by region, 2015 & 2024
  • FIG. 34 North America next generation cancer diagnostics market, 2013 - 2024 (USD Million)
  • FIG. 35 Estimated number of new cancer cases and deaths in the U.S., 2015
  • FIG. 36 U.S. next generation cancer diagnostics market, 2013 - 2024 (USD Million)
  • FIG. 37 Canada next generation cancer diagnostics market, 2013 - 2024 (USD Million)
  • FIG. 38 Europe next generation cancer diagnostics market, 2013 - 2024 (USD Million)
  • FIG. 39 Germany next generation cancer diagnostics market, 2013 - 2024 (USD Million)
  • FIG. 40 France next generation cancer diagnostics market, 2013 - 2024 (USD Million)
  • FIG. 41 Asia Pacific next generation cancer diagnostics market, 2013 - 2024 (USD Million)
  • FIG. 42 Japan next generation cancer diagnosticsmarket, 2013 - 2024 (USD Million)
  • FIG. 43 China next generation cancer diagnostics market, 2013 - 2024 (USD Million)
  • FIG. 44 Latin America next generation cancer diagnostics market, 2013 - 2024 (USD Million)
  • FIG. 45 Brazil next generation cancer diagnostics market, 2013 - 2024 (USD Million)
  • FIG. 46 MEA next generation cancer diagnostics market, 2013 - 2024 (USD Million)
  • FIG. 47 South Africa next generation cancer diagnostics market, 2013 - 2024 (USD Million)
Back to Top